- Home
- RENB vs RAND Comparison
RENB vs RAND Comparison
Compare RENB & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- RAND
- Stock Information
- Founded
- RENB 2011
- RAND 1969
- Country
- RENB United States
- RAND United States
- Employees
- RENB N/A
- RAND N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- RENB Health Care
- RAND Finance
- Exchange
- RENB Nasdaq
- RAND Nasdaq
- Market Cap
- RENB 61.0M
- RAND 52.9M
- IPO Year
- RENB N/A
- RAND N/A
- Fundamental
- Price
- RENB $0.32
- RAND $18.22
- Analyst Decision
- RENB
- RAND
- Analyst Count
- RENB 0
- RAND 0
- Target Price
- RENB N/A
- RAND N/A
- AVG Volume (30 Days)
- RENB 683.6K
- RAND 5.4K
- Earning Date
- RENB 05-19-2025
- RAND 05-05-2025
- Dividend Yield
- RENB N/A
- RAND 6.37%
- EPS Growth
- RENB N/A
- RAND 39.63
- EPS
- RENB N/A
- RAND 3.11
- Revenue
- RENB N/A
- RAND $8,499,970.00
- Revenue This Year
- RENB N/A
- RAND N/A
- Revenue Next Year
- RENB N/A
- RAND N/A
- P/E Ratio
- RENB N/A
- RAND $5.86
- Revenue Growth
- RENB N/A
- RAND 12.52
- 52 Week Low
- RENB $0.29
- RAND $13.94
- 52 Week High
- RENB $2.34
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- RENB 37.38
- RAND 42.12
- Support Level
- RENB $0.29
- RAND $18.00
- Resistance Level
- RENB $0.35
- RAND $19.70
- Average True Range (ATR)
- RENB 0.05
- RAND 0.79
- MACD
- RENB 0.01
- RAND -0.02
- Stochastic Oscillator
- RENB 18.83
- RAND 7.46
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.